Lee S. Rosen

Lee S. Rosen

Auto-generated profile, based on publicly available information

Lee S. Rosen

Developmental Therapeutics, Cancer Institute Medical Group, Santa Monica, California 90095, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2003 in Cancer
Verified
Journal Article
Open access
PDF file
LRLee S. Rosen
Lee S. Rosen
DGDavid Gordon
David Gordon
MKMary Kaminski
Mary Kaminski
AHAnthony Howell
Anthony Howell
ABAndrew Belch
Andrew Belch
JSJohn J. Seaman
John J. Seaman
BACKGROUND: The goal of the current study was to compare the long‐term (25‐month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma.METHODS: Patients (n = 1648) were randomized to receive 4 mg or 8 mg (reduced to 4 mg) zoledronic acid as a 15‐minute infusion or to receive 90 mg pamidronate as a 2‐hour infusion every 3–4 weeks for 24 months. The primary endpoint was the proportion of patients with at least 1 skeletal‐related event (SRE), defined as pathologic fracture, spinal cord compression, radiation therapy, or surgery to bone. Secondary analyses included time to first SRE, skeletal morbidity rate, and multiple‐event analysis. Hypercalcemia of malignancy (HCM) was included as an SRE in some secondary analyses.RESULTS: After 25 months of follow‐up, zoledronic acid reduced the overall proportion of patients with an SRE and reduced the skeletal morbidity rate similar to pamidronate. Compared with pamidronate, zoledronic acid (4 mg) reduced the overall risk of developing skeletal complications (including HCM) by an additional 16% (P = 0.030). In patients with breast carcinoma, zoledronic acid (4 mg) was significantly more effective than pamidronate, reducing the risk of SREs by an additional 20% (P = 0.025) compared with pamidronate and by an additional 30% in patients receiving hormonal therapy (P = 0.009). Zoledronic acid (4 mg) and pamidronate were tolerated equally well. The most common adverse events included bone pain, nausea, and fatigue.CONCLUSIONS: Long‐term follow‐up data confirm that zoledronic acid was more effective than pamidronate in reducing the risk of skeletal complications in patients with bone metastases from breast carcinoma and was of similar efficacy in patients with multiple myeloma. Cancer 2003. © 2003 American Cancer Society.DOI 10.1002/cncr.11701

1 October 2002 in Hematology/Oncology Clinics of North America
Verified
Journal Article
Closed access
LRLee S Rosen
Lee S Rosen